Rivulet Media (RIVU) 10-K 29 Dec 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2014	Dec. 24, 2014	Mar. 31, 2014
Document And Entity Information
Entity Registrant Name	Bio-Matrix Scientific Group, Inc.
Entity Central Index Key	1079282
Document Type	10-K
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$14,488,353
Entity Common Stock, Shares Outstanding		3,579,910,118
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Sep. 30, 2013
CURRENT ASSETS
Cash	$502	$116,714
Prepaid Expenses	15,000	15,000
Note Receivable	10,422	0
Interest Receivable	233	0
Total Current Assets	26,157	131,714
OTHER ASSETS
Deposits	4,200	4,200
Deferred Financing Costs	0	65,000
Available for Sale Securities	3,000	7,000
Total Other Assets	7,200	76,200
TOTAL ASSETS	33,357	207,914
CURRENT LIABILITIES
Accounts Payable	158,492	138,572
Notes Payable	379,233	219,372
Bank Overdraft	6,137	0
Accrued Payroll	587,094	612,094
Accrued Payroll Taxes	51,117	45,386
Accrued Interest	271,495	239,829
Accrued Expenses	5,000	5,000
Convertible Note Payable Net of Unamortized Discount	97,701	98,701
Due to Affiliate	0	34,895
Current portion, note payable to affiliated party	1,000	1,000
Total Current Liabilities	1,557,269	1,394,849
Total Liabilities	1,557,269	1,394,849
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($0.0001 par value) 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30, 2013 and June 30, 2014	207	207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized; 94,852 issued and outstanding as of September 30, 2013 and June 30, 2014	9	9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2013 and June 30, 2014	4	4
Series B Preferred Shares ($0.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of September 30, 2013 and June 30, 2014 respectively	73	73
Common Stock ($0.0001 par value) 5,000,000,000 shares authorized; 2,390,304,145 and 2,951,045,145 issued and outstanding as of September 30, 2013 and June 30, 2014 respectively	307,989	239,029
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2013 and June 30, 2014
Additional Paid in capital	16,510,439	14,845,671
Contributed Capital	509,355	509,355
Retained Earnings (Deficit)	22,461,356	24,542,314
Accumulated Other Comprehensive Income (Loss)	-41,333,361	-41,329,361
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	-1,543,929	-1,192,699
Noncontrolling Interest in subsidiary	20,017	5,765
Total Stockholders' Equity	-1,523,912	-1,186,934
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$33,357	$207,914

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Statement of Financial Position [Abstract]
Preferred stock; par value	$0.00	$0.00
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Preferred stock, Series AA; par value	$0.00	$0.00
Preferred stock, Series AA; shares authorized	100,000	100,000
Preferred stock, Series AA; shares issued	94,852	94,852
Preferred stock, Series AA; shares outstanding	94,852	94,852
Preferred stock, Series AAA; par value	$0.00	$0.00
Preferred stock, Series AAA; shares authorized	1,000,000	1,000,000
Preferred stock, Series AAA; shares issued	40,000	40,000
Preferred stock, Series AAA; shares outstanding	40,000	40,000
Preferred stock, Series B; par value	$0.00	$0.00
Preferred stock, Series B; shares authorized	2,000,000	2,000,000
Preferred stock, Series B; shares issued	725,409	725,409
Preferred stock, Series B; shares outstanding	725,409	725,409
Non Voting Convertible Preferred stock; par value	$1	$1
Non Voting Convertible Preferred stock; shares authorized	200,000	200,000
Non Voting Convertible Preferred stock; shares issued	0	0
Non Voting Convertible Preferred stock; shares outstanding	0	0
Common stock; par value	$0.00	$0.00
Common Stock; shares authorized	5,000,000,000	5,000,000,000
Common stock; shares issued	3,079,900,942	2,390,304,145
Common stock; shares outstanding	3,079,900,942	2,390,304,145

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
REVENUES
COST AND EXPENSES
Research and Development	23,867	9,509
General and Administrative	599,234	1,317,927
Consulting and Professional Fees	246,214	200,475
Total Costs and Expenses	869,315	1,527,911
OPERATING LOSS	-869,315	-1,527,911
OTHER INCOME & (EXPENSES)
Interest Expense	-35,136	-46,492
Loss on Settlement of Debt through Equity Issuance	-1,112,230	0
Interest Expense attributable to amortization of discount	0	-455,371
Interest Income	233	0
Securities issued pursuant to contractual obligations	0	-35,223
Other Income	490	60,000
Other Expense	-65,000	0
Total Other Income & (Expense)	-1,211,643	-477,086
NET INCOME (LOSS) before loss attributable to noncontrolling interest in Entest Biomedical, Inc. and equity in subsidiary losses	-2,080,958	-2,004,997
(Net Income) Loss attributable to noncontrolling interest in Entest Biomedical, Inc.	0	0
NET INCOME (LOSS) before equity in subsidiary losses	-2,080,958	-2,004,997
Equity in Net Income (Loss) of Entest Biomedical, Inc.	0	0
NET INCOME (LOSS)	-2,080,958	-2,004,997
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	266,234	8,833
NET INCOME (LOSS) available to common shareholders	($1,854,724)	($1,996,164)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	($0.00)	($0.00)
Weighted average number of shares outstanding	2,865,048,153	1,375,962,730

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	($2,080,959)	($2,004,997)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued for compensation to employees		62,400
Stock issued for services rendered by consultants	26,180	25,650
Stock issued for interest	3,570	5,035
Stock issued for expenses	48,000	640,000
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable	19,920	5,533
Increase (Decrease) in Accrued Expenses	12,397	351,799
Increase (Decrease) in bank Overdraft	6,137
(Increase) Decrease in Interest Receivable	-233
Increase (Decrease) in Due to Affiliate	-34,895	-4,245
(Increase) Decrease in Note Receivable	-10,422
(Increase) Decrease in Gain on cancellation of stock		-25,000
Net Cash Provided by (Used in) Operating Activities	-2,010,304	-942,935
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	100,000
Common Stock issued for Accrued Salaries		116,452
Preferred Stock issued for Accrued Salaries		10,000
Common Stock issued pursuant to Contractual Obligations		35,223
Additional paid in Capital	300,000	390,000
Principal borrowings on Convertible Debentures		555,370
Principal borrowings (repayments) on notes and Convertible Debentures	316,862	-123,148
(Increase) Decrease in Deferred Financing Costs	65,000
Loss on Settlement of Debt through Equity Issuance	1,112,230
Net Cash Provided by (Used in) Financing Activities	1,894,092	983,897
Net Increase (Decrease) in Cash	-116,212	40,962
Cash at Beginning of Period	116,714	75,752
Cash at End of Period	502	116,714
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	158,000	1,132,056
Common Shares Issued for Nonvoting Preferred		$75,000

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders Equity (USD $)	Series AA Preferred Stock	Series B Preferred Stock	Series AAA Preferred Stock	Preferred Stock	Common Stock	Nonvoting Convertible Preferred Stock	Additional Paid-In Capital	Retained Earnings	Deficit Attributable to noncontrolling interest	Noncontrolling Interest	Contributed Capital	Accumulated Other Comprehensive Income (Loss)	Total
Beginning balance, Amount at Sep. 30, 2012	$9	$73	$0	$197	$32,350	$75,000	$12,490,780	$26,547,311	$0	$0	$509,355	($41,314,361)	($1,659,286)
Beginning balance, Shares at Sep. 30, 2012	94,852	725,409	0	1,963,821	323,507,887	75,000
Common stock issued for indebtedness, Shares	0	0	0	0	595,086,442	0
Common stock issued for indebtedness, Amount	0	0	0	0	59,507	0	121,997	0	0	0	0	0	181,504
Common stock issued for interest, Shares	0	0	0	0	6,057,142	0
Common stock issued for interest, Amount	0	0	0	0	605	0	1,515	0	0	0	0	0	2,120
Shares issued pursuant to contractual obligations, Shares	0	0	0	0	111,250,000	0
Shares issued pursuant to contractual obligations, Amount	0	0	0	0	11,127	0	24,098	0	0	0	0	0	35,226
Recognition of beneficial conversion feature, convertible notes	0	0	0	0	0	0	290,000	0	0	0	0	0	290,000
Restricted Stock Award Compensation Expense recognized	0	0	0	0	0	0	26,400	0	0	0	0	0	26,400
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-11,000	-11,000
Net Income (loss)	0	0	0	0	0	0	0	-596,666	0	0	0	0	-596,666
Ending balance, Amount at Dec. 31, 2012	9	73	0	197	103,589	75,000	12,954,788	25,950,645	0	0	509,355	-41,325,361	-1,731,705
Ending balance, Shares at Dec. 31, 2012	94,852	725,409	0	1,963,821	1,035,901,471	75,000
Common stock issued for indebtedness, Shares	0	0	0	0	221,005,582	0
Common stock issued for indebtedness, Amount	0	0	0	0	22,101	0	160,574	0	0	0	0	0	182,675
Common stock issued for interest, Shares	0	0	0	0	547,828	0
Common stock issued for interest, Amount	0	0	0	0	55	0	2,465	0	0	0	0	0	2,520
Shares issued for Settlement, Shares	0	0	0	0	102,777,778	0
Shares issued for Settlement, Amount	0	0	0	0	10,277	0	644,723	0	0	0	0	0	655,000
Recognition of beneficial conversion feature, convertible notes	0	0	0	0	0	0	100,000	0	0	0	0	0	100,000
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	24,000	24,000
Net Income (loss)	0	0	0	0	0	0	0	-941,488	0	0	0	0	-941,488
Ending balance, Amount at Mar. 31, 2013	9	73	0	197	136,022	75,000	13,862,550	25,009,157	0	0	509,355	-41,301,361	-1,708,998
Ending balance, Shares at Mar. 31, 2013	94,852	725,409	0	1,963,821	1,360,232,659	75,000
Common stock issued for indebtedness, Shares	0	0	0	0	612,011,419	0
Common stock issued for indebtedness, Amount	0	0	0	0	61,201	0	351,799	0	0	0	0	0	413,000
Vesting of Restricted Stock Award	0	0	0	0	0	0	43,200	0	0	0	0	0	43,200
Common stock cancelled, Shares	0	0	0	0	-6,000,000	0
Common stock cancelled, Amount	0	0	0	0	-600	0	600	0	0	0	0	0	0
Shares issued for accrued salaries, Shares	0	0	40,000	0	26,045,795	0
Shares issued for accrued salaries, Amount	0	0	4	0	2,605	0	80,643	0	0	0	0	0	83,252
Shares issued for compensation, Shares	0	0	0	0	6,000,000	0
Shares issued for compensation, Amount	0	0	0	0	600	0	16,800	0	0	0	0	0	17,400
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-11,000	-11,000
Net Income (loss)	0	0	0	0	0	0	0	-278,789	0	0	0	0	-278,789
Ending balance, Amount at Jun. 30, 2013	9	73	4	197	199,828	75,000	14,355,592	24,730,368	0	0	509,355	-41,312,361	-1,441,935
Ending balance, Shares at Jun. 30, 2013	94,852	725,409	40,000	1,963,821	1,998,289,873	75,000
Shares of subsidiary issued for Cash, Shares	0	0	0	0	0	0
Shares of subsidiary issued for Cash, Amount	0	0	0	0	0	0	100,000	0	0	0	0	0	100,000
Shares of subsidiary issued for debt, Shares	0	0	0	0	0	0
Shares of subsidiary issued for debt, Amount	0	0	0	0	0	0	70,198	0	0	0	0	0	70,198
Common stock issued for indebtedness, Shares	0	0	0	0	346,287,898	0
Common stock issued for indebtedness, Amount	0	0	0	0	34,629	0	235,068	0	0	0	0	0	269,697
Common stock issued for preferred stock, Shares	0	0	0	0	35,714,286	-75,000
Common stock issued for preferred stock, Amount	0	0	0	0	3,571	-75,000	71,429	0	0	0	0	0	0
Common stock cancelled, Shares	0	0	0	0	-5,000,000	0
Common stock cancelled, Amount	0	0	0	0	-500	0	-24,500	0	0	0	0	0	-25,000
Shares issued for compensation, Shares	0	0	0	0	6,000,000	0
Shares issued for compensation, Amount	0	0	0	0	600	0	18,000	0	0	0	0	0	18,600
Shares issued to consultant, Shares	0	0	0	100,000	9,012,088	0
Shares issued to consultant, Amount	0	0	0	10	901	0	25,649	0	0	0	0	0	26,560
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-17,000	-17,000
Noncontrolling interest recognized	0	0	0	0	0	0	-5,765	0	0	5,765	0	0	0
Net Income (loss)	0	0	0	0	0	0	0	-188,054	0	0	0	0	-188,054
Ending balance, Amount at Sep. 30, 2013	9	73	4	207	239,029	0	14,845,671	24,542,314	0	5,765	509,355	-41,329,361	-1,186,934
Ending balance, Shares at Sep. 30, 2013	94,852	725,409	40,000	2,063,821	2,390,304,145	0
Shares of subsidiary issued for Cash, Shares	0	0	0	0	0	0
Shares of subsidiary issued for Cash, Amount	0	0	0	0	0	0	300,000	0	0	0	0	0	300,000
Common stock issued for indebtedness, Shares	0	0	0	0	390,000,000	0
Common stock issued for indebtedness, Amount	0	0	0	0	39,000	0	32,500	0	0	0	0	0	71,500
Shares issued to consultant, Shares	0	0	0	0	200,000	0
Shares issued to consultant, Amount	0	0	0	0	20	0	360	0	0	0	0	0	380
Shares issued to vendor, Shares	0	0	0	0	30,000,000	0
Shares issued to vendor, Amount	0	0	0	0	3,000	0	45,000	0	0	0	0	0	48,000
Loss recognized on issuance of shares for less than fair value	0	0	0	0	0	0	648,500	0	0	0	0	0	648,500
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-4,000	-4,000
Noncontrolling interest recognized	0	0	0	0	0	0	-6,597	0	0	6,597	0	0	0
Net Income (loss)	0	0	0	0	0	0	0	-920,888	0	0	0	0	-920,888
Ending balance, Amount at Dec. 31, 2013	9	73	4	207	281,049	0	15,865,434	23,621,426	0	12,362	509,355	-41,333,361	-1,043,442
Ending balance, Shares at Dec. 31, 2013	94,852	725,409	40,000	2,063,821	2,810,504,145	0
Common stock issued for indebtedness, Shares	0	0	0	0	140,500,000	0
Common stock issued for indebtedness, Amount	0	0	0	0	14,050	0	1,020	0	0	0	0	0	15,070
Loss recognized on issuance of shares for less than fair value	0	0	0	0	0	0	336,230	0	0	0	0	0	336,230
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	8,000	8,000
Noncontrolling interest recognized	0	0	0	0	0	0	-82,664	0	0	82,664	0	0	0
Net Income (loss)	0	0	0	0	0	0	0	-529,555	0	0	0	0	-529,555
Ending balance, Amount at Mar. 31, 2014	9	73	4	207	295,099	0	16,120,020	23,091,871	0	95,026	509,355	-41,325,361	-1,213,697
Ending balance, Shares at Mar. 31, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-6,000	-6,000
Noncontrolling interest recognized	0	0	0	0	0	0	47,466	0	0	-47,466	0	0	0
Net Income (loss)	0	0	0	0	0	0	0	-246,447	0	0	0	0	-246,447
Ending balance, Amount at Jun. 30, 2014	9	73	4	207	295,099	0	16,167,486	22,845,424	0	47,560	509,355	-41,331,361	-1,466,144
Ending balance, Shares at Jun. 30, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Common shares issued for cash, Shares	0	0	0	0	45,000,000	0
Common shares issued for cash, Amount	0	0	0	0	4,500	0	95,500	0	0	0	0	0	100,000
Common stock issued for indebtedness, Shares	0	0	0	0	75,000,000	0
Common stock issued for indebtedness, Amount	0	0	0	0	7,500	0	67,500	0	0	0	0	0	75,000
Shares issued to consultant, Shares	0	0	0	0	8,896,797	0
Shares issued to consultant, Amount	0	0	0	0	890	0	24,910	0	0	0	0	0	25,800
Loss recognized on issuance of shares for less than fair value	0	0	0	0	0	0	127,500	0	0	0	0	0	127,500
Accumulated Other Comprehensive Income (Loss)	0	0	0	0	0	0	0	0	0	0	0	-2,000	-2,000
Noncontrolling interest recognized	0	0	0	0	0	0	27,543	0	0	-27,543	0	0	0
Net Income (loss)	0	0	0	0	0	0	0	-384,068	0	0	0	0	-384,608
Ending balance, Amount at Sep. 30, 2014	$9	$73	$4	$207	$307,989	$0	$16,510,439	$22,461,356	$0	$20,017	$509,355	($41,333,361)	($1,523,912)
Ending balance, Shares at Sep. 30, 2014	94,852	725,409	40,000	2,063,821	3,079,900,942	0

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
Net Income (Loss)	($2,068,684)	($2,004,997)
Add: Unrealized Gains on Securities
Less: Unrealized Losses on Securities	-4,000	-15,000
Total Other Comprehensive Income (Loss)	-4,000	-15,000
Comprehensive Income	($2,072,684)	($2,019,997)

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc.
	From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet.
	On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring.
	As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to August 2, 2005 (date of inception), of the reverse acquisition completed on July 3, 2006, and represent the operations of BMSG.
	Through its 58% owned subsidiary, Regen BioPharma, Inc., the Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials
	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
	B. PRINCIPLES OF CONSOLIDATION
	The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and 58% owned subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011.  Significant inter-company transactions have been eliminated.
	C. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.
	D. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
	E. PROPERTY AND EQUIPMENT
	Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
	F. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments as of September 30, 2014 consisted of Securities Available for Sale consisting of 10,000,000 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $10,422 .  The fair value of Securities Available for sale as of September 30, 2014 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input.
	G. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
	H.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.
	Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.
	I. ADVERTISING
	Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the year ended September 30, 2013 and the year ended September 30, 2014 respectively.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.
	The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.
	In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.
	In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.
	In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.
	On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.
	On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:
	The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.
	Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.
	While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.
	On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.
	A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Options_and_Warrants

Options and Warrants	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
Options and Warrants	NOTE 3. OPTIONS AND WARRANTS
	As of September 30, 2014 the Company has no options or warrants outstanding.

Going_Concern

Going Concern	12 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 4. GOING CONCERN
	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $41,645,688 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $18,520,683 (excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through September 30, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management plans to raise additional funds by offering securities for cash.
	During the year ended September 30, 2014 the Company incurred net borrowings of $116,861
	During the year ended September 30, 2014 Regen sold 300,000 of its common shares for cash consideration of $300,000.
	During the year ended September 30, 2014 the Company sold 45,000,000 of its common shares for cash consideration of $100,000.

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5. INCOME TAXES
	As of September 30, 2014
	Deferred tax assets:
	Net operating tax carry forwards	$	6,535,802
	Other		-0-
	Gross deferred tax assets		6,535,802
	Valuation allowance		-6,535,802
	Net deferred tax assets	$	-0-
	As of September 30,  2014 the Company has a  Deferred Tax Asset of  $6,535,802 completely attributable to net operating loss carry forwards  of approximately $19,222,948 ( which expire 20 years from the date the loss was incurred) consisting  of
	(a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and
	(b) $19,184,332  attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Regen.
	Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.
	Income tax is calculated at the 34% Federal Corporate Rate.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS
	As of September 30, 2014 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $189,065. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum.
	As of September 30, 2014 Regen is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $30,168. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum.
	The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by Entest BioMedical, Inc. on a month to month basis free of charge. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company.
	As of September 30, 2014 Entest Biomedical, Inc. is indebted to Regen in the amount of $10,422. $10,422 lent by Regen to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	During the year ended September 30, 2014 Regen made payments totaling $18,042 dollars to Batu Biologics for contracted services . Thomas Ichim, who serves as Regen’s Chief Scientific Officer and Director of Research as well as a Director of the Company, is the Executive Chairman of and owns approximately 29% of the share capital of Batu Biologics.

Notes_Payable_and_Convertible_

Notes Payable and Convertible Notes Payable	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes Payable	NOTE 7. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE
			30-Sep-14		30-Sep-13
	Dunhill Ross Partners, Inc. ( formerly venture Bridge Advisors)		$	—	$	82,000
	Bio Technology Partners Business Trust			35,000		—
	David R. Koos ( Parent)( Note 6)			189,065		137,372
	David R. Koos ( Regen)( Note 6)			30,168		—
	The Sherman family Trust			125,000		—
	Total		$	379,233	$	219,372
	Amounts due to Dunhill Ross Partners, Inc. are due and payable at the demand of Dunhill Ross partners and bear simple interest at a rate of 10% per annum.
	Amounts due to the Biotechnology Partners Business Trust. are due and payable at the demand of Dunhill Ross partners and bear simple interest at a rate of 10% per annum.
	All loans to the Company and Regen made by David R. Koos are due and payable at the demand of Koos and bear simple interest at a rate of 15% per annum.
	All amounts due to the Sherman Family Trust bear no interest and are due and payable, in whole or in part, at the option of the holder.
	CONVERTIBLE NOTES PAYABLE SEPTEMBER 30, 2014
	$17,000	StarCity Capital LLC
	$50,000	Scott Levine
	$10,000	Mike and Ofie Weiner
	$18,400	Mike and Ofie Weiner
	$2,301	Bio Technology Partners Business Trust
	$97,701	total
	$17,000 due and payable to Starcity Capital LLC bears no interest, is payable at the demand of the Holder and permits conversion at the Holder’s option into common shares of the Company at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company has agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock.
	The amount by which the instruments as converted value exceeds the principal amount as of September 30, 2014 is $15,970.
	$50,000 due and payable to Scott Levine bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 14, 2009. No demand for payment has been made.
	$10,000 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on March 3 , 2010. No demand for payment has been made.
	$18,400 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on December 28, 2009. No demand for payment has been made.
	$2,301 due and payable to Bio Technology Partners Business Trust bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 26, 2009. No demand for payment has been made.
	As of September 30, 2014 and as of September 30, 2013 the unamortized discount on convertible notes outstanding is $0.

Stockholders_Equity

Stockholders Equity	12 Months Ended
	Sep. 30, 2014
Equity [Abstract]
Stockholders Equity	NOTE 8. STOCKHOLDERS' EQUITY
	The stockholders' equity section of the Company contains the following classes of capital stock as of September 30, 2014:
	Preferred stock, $0.0001 par value; 20,000,000 shares authorized:
	2,063,821 Preferred Shares, par value $0.0001, issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times one (1).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	94,852 Series AA Preferred Shares, par value $0.0001, issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	40,000 Series AAA Preferred Shares, par value $0.0001, issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times one hundred thousand (100,0000).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	725,409 Series B Preferred Shares, Par Value $0.0001, issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series B Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	Non Voting Convertible Preferred Stock, $1.00 Par value, 200,000 shares authorized, 0 shares issued and outstanding
	Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
	“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.
	“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.
	“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Non Voting Convertible Preferred shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	Common stock, $ 0.0001 par value; 5,000,000,000 shares authorized: 3,079,900,942 shares issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Convertible_Debentures

Convertible Debentures	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
Convertible Debentures	NOTE 9. CONVERTIBLE DEBENTURES
	At September 30, 2014, the following convertible debentures remain outstanding:
	(a) $80,701 in aggregate convertible debt  bearing simple interest at 12% per annum convertible into the Company’s common stock at $0.025 per share.
	(b) $17,000 in aggregate convertible debt bearing no interest convertible into the Company’s common stock at share and convertible into common shares of the Company at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the five trading days immediately preceding a conversion date, as reported by Bloomberg.
	Convertible Debentures described in (a) and (b) are currently due and payable. The holders have not made a demand for payment.
	As of September 30, 2014 the Aggregate Amount of Convertible Debentures outstanding was $97,701 and the Aggregate Amount of Unamortized discount was $0.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 10. COMMITMENTS AND CONTINGENCIES
	On April 12, 2013 a complaint (Complaint) was filed in the U.S. District Court Southern District of the State of new York against the Company, the Company’s Chairman and Does 1-50 by Star city Capital, LLC (“Plaintiff”) alleging securities fraud, common law fraud, negligent misrepresentation, breach of fiduciary duties and breach of contract in connection with the issuance of. The Plaintiff is also request declaratory relief from the Court.
	The action arises from the issuance and subsequent cancellation of 103,030,303 of the company’s common shares in satisfaction of $17,000 of convertible indebtedness of the Company held by the Plaintiff. The Plaintiff alleges that a cancellation notice sent by them to the Company’s transfer agent was meant to instruct the Transfer Agent simply to cancel the physical certificate in order that an equivalent number of shares may be transferred via DWAC to the Plaintiff’s stockbroker for the benefit of the Plaintiff. DWAC is the acronym for Deposit/Withdrawal At Custodian. The DWAC transaction system run by The Depository Trust Company (a.k.a. DTC or CEDE & CO) permits brokers and custodial banks, the DTC participants, to request the movement of shares to or from the issuer’s transfer agent electronically. A DWAC results in the crediting or debiting of shares to or from DTC’s book-entry account on the records of the issuer maintained by the transfer agent.
	The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself.
	The convertible indebtedness held by the Plaintiff is convertible at Holder’s demand into the common shares of the Company’s stock at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company and the Plaintiff had agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock. There can be no assurance that a subsequent conversion notice for the same amount of indebtedness issued by the Plaintiff would convert into 103,030,303 of the company’s common shares.
	On August 21, 2012 the Company entered into a settlement funding agreement with Princeton Research, Inc. and Jan Vandersande (collectively the “PRI Parties”) which obligates the Company to pay the PRI Parties $1,000 a month over thirty months.

Investment_Securities

Investment Securities	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Investment Securities	NOTE 11. INVESTMENT SECURITIES
	As of the quarter ending June 30, 2012 the Company reclassified 10,000,000 common shares of Entest (“Entest Shares”) as Securities Available for Sale from Securities Accounted for under the Equity Method. The Entest Shares are the Company’s sole Investment Securities as of September 30, 2014.

Stock_Transactions

Stock Transactions	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
Stock Transactions	NOTE 12. STOCK TRANSACTIONS
	On October 14, 2013 the Company Issued 120,000,000 Common Shares in satisfaction of $ 44,500 of indebtedness.
	On November 4. 2013 the Company Issued 200,000 Common Shares as consideration for services rendered.
	On November 13, 2013 the Company Issued 120,000,000 Common Shares in satisfaction of $ 12,000 of indebtedness.
	On December 5, 2013 the Company issued 150,000,000 Common Shares in satisfaction of $15,000 of indebtedness.
	On December 12, 2013 the Company issued 30,000,000 of its common shares to a vendor in settlement of a dispute over fees owed between the vendor and Regen.
	On October 16, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000.
	On November 15, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000.
	On December 12, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000.
	On January 23, 2014 the Company Issued 140,000,000 Common Shares in satisfaction of $ 14,070 of indebtedness.
	On January 28, 2014 the Company Issued 500,000 Common Shares in satisfaction of $ 1,000 of convertible indebtedness.
	On July 1, 2014 the Company issued 45,000,000 common shares for cash consideration of $100,000.
	On August 12, 2014 the Company issued 8,896,797 common shares with a fair value at the time of issuance of $25,800 as consideration to a consultant
	On August 18, 2014 the Company Issued 37,500,000 Common Shares in satisfaction of $ 37,500 of indebtedness.
	On August 26, 2014 the Company Issued 37,500,000 Common Shares in satisfaction of $ 37,500 of indebtedness.

Property_Dividend

Property Dividend	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
Property Dividend	NOTE 13. PROPERTY DIVIDEND
	On March 25, 2014 the Company paid a property dividend of 20,000,000 common shares of Regen Biopharma, Inc. to its shareholders. This dividend was distributed pro rata to all common and preferred shareholders of record as of March 18, 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 14. SUBSEQUENT EVENTS
	On October 1, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $ 37,500 of indebtedness.
	On October 9, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $35,000 of indebtedness.
	On October 31, 2014 the Company Issued 200,000,000 Common Shares in satisfaction of $20,000 of indebtedness.
	On December 9, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $10,000 of indebtedness.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
A. BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
B. PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION
	The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and 58% owned subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011.  Significant inter-company transactions have been eliminated.
C. USE OF ESTIMATES	C. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.
D. CASH EQUIVALENTS	D. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
E. PROPERTY AND EQUIPMENT	E. PROPERTY AND EQUIPMENT
	Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
F. FAIR VALUE OF FINANCIAL INSTRUMENTS	F. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments as of September 30, 2014 consisted of Securities Available for Sale consisting of 10,000,000 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $10,422 .  The fair value of Securities Available for sale as of September 30, 2014 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input.
G. INCOME TAXES	G. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
H. BASIC EARNINGS (LOSS) PER SHARE	H.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.
	Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.
I. ADVERTISING	I. ADVERTISING
	Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the year ended September 30, 2013 and the year ended September 30, 2014 respectively.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets:
	Net operating tax carry forwards	$	6,535,802
	Other		-0-
	Gross deferred tax assets		6,535,802
	Valuation allowance		-6,535,802
	Net deferred tax assets	$	-0-

Notes_Payable_and_Convertible_1

Notes Payable and Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Notes Payable			30-Sep-14		30-Sep-13
	Dunhill Ross Partners, Inc. ( formerly venture Bridge Advisors)		$	—	$	82,000
	Bio Technology Partners Business Trust			35,000		—
	David R. Koos ( Parent)( Note 6)			189,065		137,372
	David R. Koos ( Regen)( Note 6)			30,168		—
	The Sherman family Trust			125,000		—
	Total		$	379,233	$	219,372
Convertible Notes Payable	$17,000	StarCity Capital LLC
	$50,000	Scott Levine
	$10,000	Mike and Ofie Weiner
	$18,400	Mike and Ofie Weiner
	$2,301	Bio Technology Partners Business Trust
	$97,701	total

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Feb. 03, 2011	Jul. 03, 2006
Accounting Policies [Abstract]
Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.				100.00%
Consideration of shares of common stock of the Company				10,000,000
Cancelation of shares of the Company owned and held by John Lauring				10,000,000
Percent of voting capital stock of the Company held by former stockholder of BMSG				80.00%
Owned subsidiary, Regen BioPharma, Inc.			96.00%
Shares of Entest BioMedical, Inc. for Securities Available for Sale	10,000,000
Advertising expenses	$0	$0

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	12 Months Ended	110 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Non-cash gain upon deconsolidation ofEntest Biomedical, Inc.		$41,645,688
Net Losses		18,136,615
Equity in Net Losses of Entest Biomedical, Inc.		663,649
Net borrowings	116,861
Common stock issued for cash, Shares	45,000,000
Common stock issued for cash, Amount	$100,000

Income_Taxes_Deferred_tax_asse

Income Taxes - Deferred tax assets (Details) (USD $)	Sep. 30, 2014
Deferred tax assets:
Net operating tax carry forwards	$6,535,802
Other	0
Gross deferred tax assets	6,535,802
Valuation allowance	-6,535,802
Net deferred tax assets	$0

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Deferred tax asset	$6,535,802
Net operating loss carry forwards	19,222,948
Amount of NOL acuired in reverse aquisition fo BMSG	38,616
Amount of NOL attributable to Bio-Matrix Scientific Group, Inc.	$19,184,332
Federal Corporate income tax Rate	34.00%

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
Amount due to CEO	$189,065
Simple interest rate on notes due to CEO	15.00%
Total payment amount due to Entest	10,422
Payments for services from Batu Biologics	$18,042

Notes_Payable_and_Convertible_2

Notes Payable and Convertible Notes Payable - Notes Payable (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Debt Disclosure [Abstract]
Dunhill Ross Partners, Inc. ( formerly Venture Bridge Advisors)		$82,000
Bio Technology Partners Business Trust	35,000
David R. Koos ( Parent)( Note 6)	189,065	137,372
David R. Koos ( Regen)( Note 6)	30,168
The Sherman Family Trust	125,000
Total	$379,233	$219,372

Notes_Payable_and_Convertible_3

Notes Payable and Convertible Notes Payable - Convertible Notes Payable (Details) (USD $)	Sep. 30, 2014
Debt Disclosure [Abstract]
StarCity Capital LLC	$17,000
Scott Levine	50,000
Mike and Ofie Weiner	10,000
Mike and Ofie Weiner	18,400
Bio Technology Partners Business Trust	2,301
Total	$97,701

Stockholders_Equity_Details_Na

Stockholders Equity (Details Narrative) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Equity [Abstract]
Preferred stock; par value	$0.00	$0.00
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Preferred stock, Series AA; par value	$0.00	$0.00
Preferred stock, Series AA; shares authorized	100,000	100,000
Preferred stock, Series AA; shares issued	94,852	94,852
Preferred stock, Series AA; shares outstanding	94,852	94,852
Preferred stock, Series AAA; par value	$0.00	$0.00
Preferred stock, Series AAA; shares authorized	1,000,000	1,000,000
Preferred stock, Series AAA; shares issued	40,000	40,000
Preferred stock, Series AAA; shares outstanding	40,000	40,000
Preferred stock, Series B; par value	$0.00	$0.00
Preferred stock, Series B; shares authorized	2,000,000	2,000,000
Preferred stock, Series B; shares issued	725,409	725,409
Preferred stock, Series B; shares outstanding	725,409	725,409
Non Voting Convertible Preferred stock; par value	$1	$1
Non Voting Convertible Preferred stock; shares authorized	200,000	200,000
Non Voting Convertible Preferred stock; shares issued	0	0
Non Voting Convertible Preferred stock; shares outstanding	0	0
Common stock; par value	$0.00	$0.00
Common Stock; shares authorized	5,000,000,000	5,000,000,000
Common stock; shares issued	3,079,900,942	2,390,304,145
Common stock; shares outstanding	3,079,900,942	2,390,304,145

Convertible_Debentures_Details

Convertible Debentures (Details Narrative) (USD $)	Sep. 30, 2014
Aggregate Amount of Unamortized discount	$0
Aggregate Amount of Convertible Debentures outstanding	97,701
Convertible Debenture A
Face value of convertible debenture sold	80,701
Interest accrued on the Convertible Debenture, per annum	12.00%
Common shares conversion rate	$0.03
Convertible Debenture B
Face value of convertible debenture sold	$17,000
Interest accrued on the Convertible Debenture, per annum	5.00%
Common shares conversion rate	$0.03
Converted discount rate of note	55.00%

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended
	Aug. 31, 2012	Apr. 12, 2013
Commitments and Contingencies Disclosure [Abstract]
Cancellation of company common shares held by Plaintiff		103,030,303
Satisfaction of convertible indebtedness held by Plaintiff		$17,000
Limitation on conversion of outstanding common stock		9.99%
Settlement with PRI Parties, payment per month	$1,000

Investment_Securities_Details_

Investment Securities (Details Narrative) (USD $)	Jun. 30, 2012
Accounting Policies [Abstract]
Common shares of Entest reclassified as Securities Available for Sale	$10,000,000

Stock_Transactions_Details_Nar

Stock Transactions (Details Narrative) (USD $)	Aug. 26, 2014	Aug. 18, 2014	Aug. 12, 2014	Jul. 02, 2014	Jan. 28, 2014	Jan. 23, 2014	Dec. 12, 2013	Dec. 05, 2013	Nov. 15, 2013	Nov. 13, 2013	Nov. 04, 2013	Oct. 16, 2013	Oct. 14, 2013
Notes to Financial Statements
Common stock issued for debt, Shares	37,500,000	37,500,000			500,000	140,000,000		150,000,000		120,000,000			120,000,000
Common stock issued for debt, Amount	$37,500	$37,500			$1,000	$14,070		$15,000		$12,000			$44,500
Common stock issued for services, Shares			8,896,797								200,000
Common stock issued for services, Amount			25,800
Common stock issued for settlement							30,000,000
Regen common stock issued for cash, Shares							100,000		100,000			100,000
Regen common stock issued for cash, Amount							100,000		100,000			100,000
Common stock issued for cash, Shares				45,000,000
Common stock issued for cash, Amount				$100,000

Property_Dividend_Details_Narr

Property Dividend (Details Narrative)	1 Months Ended
	Mar. 31, 2014
Notes to Financial Statements
Regen common stock issued to shareholders	20,000,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	Dec. 09, 2014	Oct. 31, 2014	Oct. 09, 2014	Oct. 01, 2014
Subsequent Events [Abstract]
Common stock issued for debt, Shares	100,000,000	200,000,000	100,000,000	100,000,000
Common stock issued for debt, Amount	$10,000	$20,000	$35,000	$37,500